DelveInsight’s, “Immune Thrombocytopenic Purpura - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Immune Thrombocytopenic Purpurapipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Immune Thrombocytopenic PurpuraUnderstanding
Acquired Hemophilia A: Overview
Immune thrombocytopenic purpura (ITP) is a blood disorder characterized by a decrease in the number of platelets in the blood. Platelets are cells in the blood that help stop bleeding. A decrease in platelets can cause easy bruising, bleeding gums, and internal bleeding. This disease is caused by an immune reaction against one's own platelets. It has also been called autoimmune thrombocytopenic purpura.

"Immune Thrombocytopenic Purpura- Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune Thrombocytopenic Purpurapipeline landscape is provided which includes the disease overview and Immune Thrombocytopenic Purpuratreatment guidelines. The assessment part of the report embraces, in depth Immune Thrombocytopenic Purpuracommercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune Thrombocytopenic Purpuracollaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
● The companies and academics are working to assess challenges and seek opportunities that could influence Immune Thrombocytopenic PurpuraR&D. The therapies under development are focused on novel approaches to treat/improve Acquired Hemophilia A.

Immune Thrombocytopenic PurpuraEmerging Drugs Chapters
This segment of the Immune Thrombocytopenic Purpurareport encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Immune Thrombocytopenic PurpuraEmerging Drugs
● Rozanolixizumab: UCB
Rozanolixizumab is a subcutaneously administered, humanized monoclonal antibody that specifically binds, with high affinity, to human FcRn. It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies. The drug is in phase 3 of clinical trials for the treatment of Idiopathic thrombocytopenic purpura.

● Rilzabrutinib: Principia Biopharma
Rilzabrutinib is oral, first in class, wholly owned BTK inhibitor (formerly known as PRN1008), is currently being evaluated in three different disease indications. Rilzabrutinib is also being evaluated in patients with ITP, a rare autoimmune disease that causes high risk for bleeding, excessive bruising, fatigue and potential for life threatening intracranial bleeding due to destruction of platelets. The drug is in phase 3 of clinical trials for the treatment of Idiopathic thrombocytopenic purpura.

● Efgartigimod: argenx
Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. The drug is in phase 3 of clinical trials for the treatment of Idiopathic thrombocytopenic purpura.
Further product details are provided in the report……..

Acquired Hemophilia A: Therapeutic Assessment
This segment of the report provides insights about the different Immune Thrombocytopenic Purpuradrugs segregated based on following parameters that define the scope of the report, such as:
● Major Players in Acquired Hemophilia A
There are approx. 10+ key companies which are developing the therapies for Acquired Hemophilia A. The companies which have their Immune Thrombocytopenic Purpuradrug candidates in the most advanced stage, i.e. phase III include, UCB.

● Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration
Immune Thrombocytopenic Purpurapipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Subcutaneous
• Intravenous
• Intramuscular
● Molecule Type

Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
● Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acquired Hemophilia A: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Immune Thrombocytopenic Purpuratherapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immune Thrombocytopenic Purpuradrugs.

Immune Thrombocytopenic PurpuraReport Insights
• Immune Thrombocytopenic PurpuraPipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Immune Thrombocytopenic PurpuraReport Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Immune Thrombocytopenic Purpuradrugs?
• How many Immune Thrombocytopenic Purpuradrugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acquired Hemophilia A?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Immune Thrombocytopenic Purpuratherapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Immune Thrombocytopenic Purpuraand their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• UCB
• Principia Biopharma
• Argenx
• HanAll Biopharma
• Momenta Pharmaceuticals
• Genosco
• Takeda
• Bioverativ
• Hutchison Medipharma Limited

Key Products
• Rozanolixizumab
• Rilzabrutinib
• Efgartigimod
• Batoclimab
• M254
• Cevidoplenib
• Mezagitamab
• BIVV020
• HMPL-523